Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001332132 | SCV001524349 | uncertain significance | MPI-congenital disorder of glycosylation | 2019-02-08 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001332132 | SCV001569311 | uncertain significance | MPI-congenital disorder of glycosylation | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with alanine at codon 331 of the MPI protein (p.Glu331Ala). The glutamic acid residue is weakly conserved and there is a moderate physicochemical difference between glutamic acid and alanine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with MPI-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001332132 | SCV002089789 | uncertain significance | MPI-congenital disorder of glycosylation | 2020-04-29 | no assertion criteria provided | clinical testing |